Semaglutide: An analysis of the effects of its use in the fight against obesity
DOI:
https://doi.org/10.52076/eacad-v5i2.553Keywords:
Glucagon-Like Peptide-1 Receptor Agonists; Diabetes Mellitus; Obesity; Adverse effects.Abstract
Obesity is a chronic disease that affects 650 million people worldwide. As a treatment, there is a reduction in caloric intake, regular practice of physical activity and there may also be an association with medications that promote the loss of body fat. In this context, semaglutide-based drugs appear, which have as their main objective the treatment of Diabetes Mellitus type 2, but which have weight loss as a side effect, such as Ozempic. The present study aims to understand how semaglutide contributes to the loss of body fat and raise positive and negative points of the use of this substance in the treatment of obesity through a narrative literature review. After analyzing the articles selected from the Virtual Health Library database and texts searched online, significant loss of body weight, reduction of plasma glucose and reduction of risk of cardiovascular accidents were found as positive results. However, the main adverse effects reported were gastrointestinal changes, thyroid tumors, psychological disorders, and significant weight regain after discontinuation of treatment.
References
Algarni, M. A. et al. (2023). Knowledge and Attitude of the General Population in Saudi Arabia Toward Weight Management Medications (WMMs): A Cross-Sectional Study. Cureus. 15(8), 2023.
Alves, B. / O. / O.-M. 04/3 – Dia Mundial da Obesidade | Biblioteca Virtual em Saúde MS. https://bvsms.saude.gov.br/04-3-dia-mundial-da-obesidade/.
Barton, J. R. et al. (2023). Enteroendocrine cell regulation of the gut-brain axis. Frontiers in Neuroscience, v. 17, 7 nov. 2023.
Baser, O. et al. (2024). The association between weight loss medications and cardiovascular complications. Obesity, 6 maio 2024.
Davide A. et al. (2023). GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. Brain Sciences, 13(11), 1503–1503, 24 out. 2023.
Feier, C. V. I. et al. (2024). Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. International Journal of Molecular Sciences, 25(8), 4346, 1 jan. 2024.
FDA. FDA (2014). Approves New Drug Treatment for Chronic Weight Management, First Since 2014. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014.
Guyton, A. C. (2009). Fisiologia Humana. Editora Guanabara Koogan S.A. (12ª ed.). Rio de Janeiro,2009.
Han, S. H. et al. (2023). Public Interest in the Off-Label Use of Glucagon-Like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis. Aesthetic Surgery Journal, 44(1), 4 jul. 2023.
Horvatich, G. (2023). Semaglutida em pauta. 2023. https://site.cff.org.br/noticia/noticias-do-cff/07/02/2023/semaglutida-em-pauta.
Klair, N. et al. (2023). What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue. Cureus, 15(9), 29 set. 2023.
LE, R D K; LE, K; & FOO, F. (2024). The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review. PubMed, 12(1), 8 jan. 2024.
Long, B; Pelletier, J; Koyfman, A; Bridwell, R E. (2024). GLP-1 agonists: A review for emergency clinicians. The American Journal of Emergency Medicine, [S. l.], 78, 89-94, 5 abr. 2024.
Mawardi, H. H. et al. (2023). Semaglutide-associated hyposalivation: A report of case series. Medicine, 102(52), e36730–e36730, 29 dez. 2023.
Mota de Sousa, L. M. et al(2018). Revisões da literatura científica: tipos, métodos e aplicações em enfermagem. Revista Portuguesa de Enfermagem de Reabilitação, 1(1), 45–55, 23 jun. 2018.
NACIONAL, I. (2022). RESOLUÇÃO-RE No 4.310, DE 29 DE DEZEMBRO DE 2022 - DOU - Imprensa Nacional. https://www.in.gov.br/en/web/dou/-/resolucao-re-n-4.310-de-29-de-dezembro-de-2022-455452640.
O’Neill, E. S. et al. (2024). Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future. Plastic and Reconstructive Surgery – Global Open, 12(1), e5516, 1 jan. 2024.
Sabbá, H B O et al. (2022). Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysis. Research, Society and Development, 11(11), e587111133963, 4 set. 2022.
Shahad Sabaawi Ibrahim et al. (2024). The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. Cancer and metastasis reviews/Cancer metastasis reviews, 27 maio 2024.
Watanabe, J. H.; Kwon, J; Nam, B; & Reikes, A.(s.d.). Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. Journal of the American Pharmacists Association.
Wilding, J. P. H.; Batterham, R. L.& Calanna, S. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002, 10 fev. 2021.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Lorranny Vitoria Niquini Ribeiro; Elismar dos Santos Dias Junior; Paula Fonseca Sena de Azevedo; Pedro Henrique dos Santos Carneiro de Oliveira; Giovanna Gomes Cordeiro; Henrique Soares Pinheiro; Kemile Albuquerque Leão
This work is licensed under a Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
